| Document |
Document Title |
|
WO/2005/030736 |
A description follows of 1,3-diones having general formula (I): together with their use as herbicides for the control of weeds in agricultural crops.
|
|
WO/2005/030739 |
The present invention relates to methods for the preparation of benzoxazole sulfonamide compounds of formula (9) as well as novel intermediates of formula (6) for use in said method. More in particular the invention relates to methods fo...
|
|
WO/2005/030704 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2005/030700 |
Certain ß-amino acids that bind to the alpha-2-delta (a2S) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other d...
|
|
WO/2005/028426 |
A compound of the present invention and pharmaceutically acceptable salts thereof are represented by the following general formula (1). (1) (In the formula (1), the definitions of R1, R2, R3, R4, R5, R6, Q, R8 and R9 are the same as thos...
|
|
WO/2005/028413 |
A process for producing an optically active cyclopropane compound represented by the formula (4): (4) (wherein R3, R4, R5, and R6 are the same or different and each represents hydrogen, halogeno, (un)substituted alkyl, etc.; R7 represent...
|
|
WO/2005/028454 |
The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, a...
|
|
WO/2005/028445 |
Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R 1 is halogen, hydroxy, C 1-6 álkyl, h...
|
|
WO/2005/026114 |
This invention relates to a novel series of chemical compounds useful as Human immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents. The invention further relates to pharmaceutical composi...
|
|
WO/2005/026134 |
Compounds of the formula (I) provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the...
|
|
WO/2005/026137 |
The present invention relates to modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including CF Transmembrane Regulator ('CFTR'), compositions thereof, and methods therewith. The present invention also relates...
|
|
WO/2005/023801 |
The invention relates to intermediate products (ZP) for a novel and efficient synthesis of compounds, wherein the pharmacophores of quinolone and oxazolidinone are linked together by means of a chemically stable linker.
|
|
WO/2005/023777 |
Disclosed is a compound for selectively activating PPAR &agr which is represented by the following general formula (1): (1) (wherein R1 and R2 may be the same or different and represent hydrogen atoms or the like; R3a, R3b, R4a and R4b m...
|
|
WO/2005/023261 |
The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be su...
|
|
WO/2005/023765 |
The invention provides a method of preparing a compound of formula (2), wherein R1 and R6 are as defined herein, by a catalytic amidation process in the presence of added carbon dioxide. The inventive methods show surprising rate enhance...
|
|
WO/2005/021503 |
Compounds of formula (I): wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.
|
|
WO/2005/020897 |
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8...
|
|
WO/2005/021517 |
The invention relates to a method of preparing urethane-protected N-carboxyanhydrides of alpha amino acids. The inventive method enables the synthesis of urethane-protected N-carboxyanhydrides of alpha amino acids in the presence of a ca...
|
|
WO/2005/019174 |
The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositio...
|
|
WO/2005/019184 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/019213 |
The present invention provides antibacterial agents having the formulae (I) and (II) as described herein.
|
|
WO/2005/019214 |
Compounds of formula (I) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of fo...
|
|
WO/2005/019212 |
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
|
|
WO/2005/019151 |
The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator acti...
|
|
WO/2005/019211 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at le...
|
|
WO/2005/016344 |
This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1 to R5 are defined in the description, and to processes for the preparation thereof, intermediates used ...
|
|
WO/2005/016888 |
It is intended to provide a compound highly specific to amyloid β-protein to be used in diagnosing diseases with amyloid β-protein accumulation, a staining agent specific to amyloid β-protein and treating and preventing diseases with ...
|
|
WO/2005/016898 |
The invention relates to a stable polymorphic form of the compound 7-[4-([1,1'-biphenyl] -3-ylmethyl)-l -piperazinyl]2(3H)-benzoxazolone monomethanesulfonate (INNM bifeprunox mesylate), a method for the preparation of said polymorphic ...
|
|
WO/2005/016862 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2005/016384 |
It is intended to provide a compound having a high specificity for amyloid β protein which is usable in diagnosing a disease with amyloid β protein deposit, a staining agent specific for amyloid β protein and treating and preventing a...
|
|
WO/2005/016338 |
The use of a 5HT2B receptor antagonist for the manufacture of a medicament for the treatment of congestive heart failure.
|
|
WO/2005/016866 |
The present invention is to provide a method for producing the desired optically active β-amino acid derivatives of high optical purities in high yields, without requiring a step of deprotection. More particularly, the present invention...
|
|
WO/2005/016267 |
The present invention relates to compounds of the Formula (I), wherein R3, R5, R6, R7, and Z, and other variables enumerated under one or more of R3, R5, R6, R7, and Z, are as defined. Compounds of the Formula (I) have activity inhibitin...
|
|
WO/2005/013914 |
The present invention relates to compounds such as those of formula (I-A) inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and met...
|
|
WO/2005/014563 |
The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerativ...
|
|
WO/2005/012220 |
The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation. Formula (I) inc...
|
|
WO/2005/012263 |
Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT2B receptor.
|
|
WO/2005/012270 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of biaryl heterocyclic amines, amides, and sulfur-...
|
|
WO/2005/012297 |
Leukotriene A4 hydrolase (LTA4H) inhibitors of Formula (I), compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated ...
|
|
WO/2005/012271 |
The present invention relates to processes for the preparation of biaryl oxazolidinones. These compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
|
|
WO/2005/012221 |
A compound represented by the general formula (I): (wherein rings A, B, and D each independently represents an optionally substituted cyclic group; W represents a spacer whose main chain has 1 to 8 atoms; X represents a spacer whose main...
|
|
WO/2005/012228 |
The invention relates to novel o ptical recording materials that comprise specific and in some cases novel diketone enamines or metal chelates thereof and that have excellent recording and playback quality especially ata wavelength of 35...
|
|
WO/2005/012296 |
Leukotriene A4 hydrolase (LTA4H) inhibitors of formula I, compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated wi...
|
|
WO/2005/009940 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2005/009998 |
This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers...
|
|
WO/2005/009981 |
The invention relates to surface-functionalized support materials, respectively comprising a polymer surface and at least one linker compound which is bonded to said surface in a covalent manner, as well as to the production and use ther...
|
|
WO/2005/009951 |
The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory a...
|
|
WO/2005/009941 |
The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.
|
|
WO/2005/007616 |
The present invention relates to diphenylamino ketone derivatives, pharmaceutical compositions and methods of use thereof.
|
|
WO/2005/005456 |
Novel PDF inhibitors and novel methods for their use are provided.
|
